Network Pharmacology Integrated Molecular Docking Reveals the Antiosteosarcoma Mechanism of Biochanin A

Abstract EN

Background.

As the malignant tumor with the highest incidence in teenagers, osteosarcoma has become a major problem in oncology research.

In addition to surgical management, the pharmacotherapeutic strategy for osteosarcoma treatment is an attractive way to explore.

It has been demonstrated that biochanin A has an antitumor capacity on multiple kinds of solid tumor, including osteosarcoma.

But the precise mechanism of biochanin A against osteosarcoma is still needed to be discovered.

Objective.

To identify the potential therapeutic targets of biochanin A in treating osteosarcoma.

Methods.

In present study, an integrated approach including network pharmacology and molecular docking technique was conducted, which mainly comprises target prediction, network construction, gene ontology, and pathway enrichment.

CCK8 test was employed to evaluate the cell viability of MG63 cells.

Western-blot was used to verify the target proteins of biochanin A.

Results.

Ninety-six and 114 proteins were obtained as the targets of biochanin A and osteosarcoma, respectively.

TP53, IGF1, JUN, BGLAP, ATM, MAPK1, ATF3, H2AFX, BAX, CDKN2A, and EGF were identified as the potential targets of biochanin A against osteosarcoma.

Based on the western-blot detection, the expression of BGLAP, BAX, and ATF3 in MG63 cell line changed under the treatment of biochanin A.

Conclusion.

Biochanin A can effectively suppress the proliferation of osteosarcoma and regulate the expression of BGLAP, BAX, and ATF3, which may act as the potential therapeutic targets of osteosarcoma.